Skip to main content
SpringerLink
Log in

Aktuelle Diagnostik und Therapie der Migräne

Current diagnosis and treatment of migraine

  • CME Weiterbildung • Zertifizierte Fortbildung
  • Published:
Der Schmerz Aims and scope Submit manuscript

Zusammenfassung

Kopfschmerzen gehören zu den am häufigsten beklagten Beschwerden und Symptomen in der ärztlichen Praxis. Die Migräne ist mit einer Prävalenz von 8% bei Männern und 12–15% bei Frauen die zweithäufigste Kopfschmerzform. In den letzten 100 Jahren hat sich ein dramatischer Wissenszuwachs in den Bereichen Epidemiologie, Pathophysiologie, Akuttherapie und präventive Behandlung der Migräne ergeben. Zum Durchbruch in der Akutbehandlung von Migräneattacken führte die Entdeckung der Triptane. Für die medikamentöse Migräneprophylaxe stehen β-Rezeptoren-Blocker, Kalziumantagonisten und Neuromodulatoren zur Verfügung. Eine wichtige Rolle spielt die nichtmedikamentöse Migräneprophylaxe. Neue Versorgungsstrukturen, wie die Integrierte Versorgung Kopfschmerz, gewährleisten eine bessere Versorgung von Patienten mit Migräne, insbesondere chronischer Migräne.

Abstract

Headaches are one of the most common disorders and symptoms in daily medical practice. The prevalence of migraine is 8% in men and 12–15% in women. Dramatic progress in the areas of epidemiology, pathophysiology, and acute and preventive therapy of migraine has been made over the past 100 years, with triptans being the breakthrough for treating acute migraine attacks. Beta blockers, calcium antagonists, and neuromodulators are available for preventive migraine therapy. Nonpharmacologic treatment also plays an important role in migraine prevention. New medical care structures such as integrated headache care provide better support for patients with migraine, particularly those with chronic migraine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ahonen K, Hamalainen ML, Eerola M et al. (2006) A randomized trial of rizatriptan in migraine attacks in children. Neurology 67: 1135–1140

    Article  PubMed  CAS  Google Scholar 

  2. Aurora SK, Gawel M, Brandes JL et al. (2007) Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 47: 486–499

    Article  PubMed  Google Scholar 

  3. Ayata C, Jin H, Kudo C et al. (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59: 652–661

    Article  PubMed  CAS  Google Scholar 

  4. Bigal ME, Lipton RB (2006) Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 67: 252–257

    Article  PubMed  Google Scholar 

  5. Bousser M-G (2006) Patent foramen ovale and migraine: evidence for a link? Headache Curr 3: 44–51

    Article  Google Scholar 

  6. Brandes JL, Kudrow D, Stark SR et al. (2007) Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 297: 1443–1454

    Article  PubMed  CAS  Google Scholar 

  7. Bussone G, Diener H, Pfeil J et al. (2005) Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 59: 961–968

    Article  PubMed  CAS  Google Scholar 

  8. Creutzig A, Alexander K (1985) Ergotismus. Dtsch Med Wochenschr 110: 1420–1422

    PubMed  CAS  Google Scholar 

  9. Dahloef CG (2006) Infrequent or non-response to oral sumatriptan does not predict response to other triptans – review of four trials. Cephalalgia 26: 98–106

    Article  Google Scholar 

  10. Dichgans J, Diener HC, Gerber WD et al. (1984) Analgetika-induzierter Dauerkopfschmerz. Dtsch Med Wochenschr 109: 369–373

    Article  PubMed  CAS  Google Scholar 

  11. Diener HC (2005) Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg. Curr Med Res Opin 21: 1603–1610

    Article  PubMed  CAS  Google Scholar 

  12. Diener HC, for the ASASUMAMIG Study Group (1999) Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 19: 581–588

    Article  PubMed  CAS  Google Scholar 

  13. Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3: 475–483

    Article  PubMed  Google Scholar 

  14. Diener H, Limmroth V, Fritsche G et al. (2005) Therapie der Migräneattacke und Migräneprophylaxe. Leitlinie der Deutschen Gesellschaft für Neurologie und der Deutschen Migräne- und Kopfschmerzgesellschaft. In: Diener H, für die Kommission Leitlinien der DGN (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie, 3. Aufl. Thieme, Stuttgart New York

  15. Diener H, Pfaffenrath V, Pageler L et al. (2005) The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 25: 776–778

    Article  PubMed  CAS  Google Scholar 

  16. Diener HC, Kronfeld K, Boewing G et al. (2006) Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet Neurol 5: 310–316

    Article  PubMed  Google Scholar 

  17. Diener H, Bussone G, Van Oene J et al. (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia in press

  18. Diener HC, Kurth T, Dodick D (2007) Patent foramen ovale and migraine. Curr Pain Headache Rep 11: 236–240

    Article  PubMed  Google Scholar 

  19. Diener HC, Kurth T, Dodick D (2007) Patent foramen ovale, stroke, and cardiovascular disease in migraine. Curr Opin Neurol 20: 310–319

    Article  PubMed  Google Scholar 

  20. Dodick D, Lipton R, Martin V et al. (2004) Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44: 414–425

    Article  PubMed  Google Scholar 

  21. Dodick DW, Martin VT, Smith T et al. (2004) Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache [Suppl 1] 44: S20–30

  22. Dodick DW, Mauskop A, Elkind AH et al. (2005) Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45: 315–324

    Article  PubMed  Google Scholar 

  23. Dowson AJ, Wilmshurst P, Muir KW et al. (2006) A prospective, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy of patent foramen ovale closure with the STARFlex septal repair implant to prevent refractory migraine headaches: the MIST trial. Neurology 67: 185

    Article  Google Scholar 

  24. Eulenburg A (1887) Zur Aetiologie und Therapie der Migräne. Wien Med Presse 28: 3–8

    Google Scholar 

  25. Fasmer OB (2001) The prevalence of migraine in patients with bipolar and unipolar affective disorders. Cephalalgia 21: 894–899

    Article  PubMed  CAS  Google Scholar 

  26. Ferrari MD, Roon KI, Lipton RB et al. (2001) Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358: 1668–1675

    Article  PubMed  CAS  Google Scholar 

  27. Fiore M, Shields KE, Santanello N et al. (2005) Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia 25: 685–688

    Article  PubMed  CAS  Google Scholar 

  28. Fox AW, Chambers CD, Anderson PO et al. (2002) Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 42: 8–15

    Article  PubMed  Google Scholar 

  29. Füeßel H (1987) Chronischer Ergotismus. Selecta 33: 20063

    Google Scholar 

  30. Goldstein J, Silberstein SD, Saper JR et al. (2006) Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 46: 444–453

    Article  PubMed  Google Scholar 

  31. Goldstein J, Tiseo PT, Albert KS ert al. (2006) Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 46: 1142–1150

    Article  PubMed  Google Scholar 

  32. Hadjikhani N, Sanchez del Rio M, Wu O et al. (2001) Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 98: 4687–4692

    Article  PubMed  CAS  Google Scholar 

  33. Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia [Suppl 7] 8: 1–93

    Google Scholar 

  34. Horton BT, Peters GA (1963) Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 3: 214–226

    Article  Google Scholar 

  35. Humphrey PPA, Feniuk W, Perren M et al. (1989) Sumatriptan succinate. Drugs Future 14: 35–39

    Google Scholar 

  36. Källen B, Lygner PE (2001) Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 41: 351–356

    Article  PubMed  Google Scholar 

  37. Kavuk I YA, Cetindere U, Agelink MW et al. (2003) Epidemiology of chronic daily headache. Eur J Med Res 8: 236–240

    PubMed  CAS  Google Scholar 

  38. Kirchmann M, Thomsen LL, Olesen J (2006) Basilar-type migraine: clinical, epidemiologic, and genetic features. Neurology 66: 880–886

    Article  PubMed  Google Scholar 

  39. Kurth T, Slomke MA, Kase CS et al. (2005) Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 64: 1020–1026

    PubMed  CAS  Google Scholar 

  40. Kurth T, Gaziano JM, Cook NR et al. (2006) Migraine and risk of cardiovascular disease in women. JAMA 296: 283–291

    Article  PubMed  CAS  Google Scholar 

  41. Kurth T, Holtmann G, Neufang-Huber J et al. (2006) Prevalence of unexplained upper abdominal symptoms in patients with migraine. Cephalalgia 26: 506–510

    Article  PubMed  CAS  Google Scholar 

  42. Kurth T, Gaziano JM, Cook NR et al. (2007) Migraine and risk of cardiovascular disease in men. Arch Intern Med 167: 795–801

    Article  PubMed  Google Scholar 

  43. Lanteri-Minet M, Radat F, Chautard MH et al. (2005) Anxiety and depression associated with migraine: influence on migraine subjects‘ disability and quality of life, and acute migraine management. Pain 118: 319–326

    Article  PubMed  Google Scholar 

  44. Leinisch E, Evers S, Kaempfe N et al. (2005) Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: a double-blind, placebo-controlled parallel group multicenter study. Pain 117: 396–400

    Article  PubMed  CAS  Google Scholar 

  45. Lewis D, Ashwal S, Hershey A et al. (2004) Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 63: 2215–2224

    PubMed  CAS  Google Scholar 

  46. Limmroth V, Katsarava Z, Fritsche G et al. (2002) Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59: 1011–1014

    PubMed  CAS  Google Scholar 

  47. Linde K, Streng A, Jurgens S et al. (2005) Acupuncture for patients with migraine: a randomized controlled trial. JAMA 293: 2118–2125

    Article  PubMed  CAS  Google Scholar 

  48. MacGregor EA, Frith A, Ellis J et al. (2006) Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 67: 2159–2163

    Article  PubMed  CAS  Google Scholar 

  49. Mannix LK, Savani N, Landy S et al. (2007) Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 47: 1037–1049

    Article  PubMed  Google Scholar 

  50. Neuhauser HK, Radtke A, Brevern M von et al. (2006) Migrainous vertigo: prevalence and impact on quality of life. Neurology 67: 1028–1033

    Article  PubMed  CAS  Google Scholar 

  51. O’Quinn S, Ephross SA, Williams V et al. (1999) Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 263: 7–12

    Article  Google Scholar 

  52. Oedegaard KJ, Neckelmann D, Mykletun A et al. (2006) Migraine with and without aura: association with depression and anxiety disorder in a population-based study. The HUNT Study. Cephalalgia 26: 1–6

    Article  PubMed  CAS  Google Scholar 

  53. Olesen C, Steffensen FH, Sorensen HT et al. (2000) Pregnancy outcome following prescription for sumatriptan. Headache 40: 20–24

    Article  PubMed  CAS  Google Scholar 

  54. Olesen J, Bousser M-G, Diener H et al. for the International Headache Society (2004) The international classification of headache disorders, 2nd edn. Cephalalgia [Suppl 1] 24: 1–160

  55. Olesen J, Diener H, Husstedt IW et al. for the BIBN 4096 BS Clinical Proof of Concept Study Group (2004) Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med 350: 1104–1110

    Article  PubMed  CAS  Google Scholar 

  56. Paemeleire K, Bahra A, Evers S et al. (2006) Medication-overuse headache in patients with cluster headache. Neurology 67: 109–113

    Article  PubMed  CAS  Google Scholar 

  57. Peters GA, Horton BT (1951) Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc Staff Meet Mayo Clin 26: 153–161

    PubMed  CAS  Google Scholar 

  58. Radat F, Swendsen J (2005) Psychiatric comorbidity in migraine: a review. Cephalalgia 25: 165–178

    Article  PubMed  CAS  Google Scholar 

  59. Rothner AD, Wasiewski W, Winner P et al. (2006) Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache 46: 101–109

    Article  PubMed  Google Scholar 

  60. Sanchez del Rio M, Bakker D, Wu O et al. (1999) Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 19: 701–707

    Article  Google Scholar 

  61. Scher AI, Bigal ME, Lipton RB (2005) Comorbidity of migraine. Curr Opin Neurol 18: 305–310

    Article  PubMed  Google Scholar 

  62. Scher A, Terwindt G, Picavet H et al. (2005) Cardiovascular risk factors and migraine: the GEM population-based study. Neurology 64: 614–620

    PubMed  CAS  Google Scholar 

  63. Schulman E, Dermott K (2003) Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 43: 729–733

    Article  PubMed  Google Scholar 

  64. Schwartz BS, Stewart WF, Simon D et al. (1998) Epidemiology of tension-type headache. JAMA 279: 381–383

    Article  PubMed  CAS  Google Scholar 

  65. Shuhaiber S, Pastuszak A, Schick B et al. (1998) Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 51: 581–583

    PubMed  CAS  Google Scholar 

  66. Silberstein SD, Lipton RB (1993) Epidemiology of migraine. Neuroepidemiology 12: 179–194

    Article  PubMed  CAS  Google Scholar 

  67. Silberstein SD, Lipton RB, Dodick DW et al. (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47: 170–180

    Article  PubMed  Google Scholar 

  68. Silvestrini M, Bartolini M, Coccia M et al. (2003) Topiramate in the treatment of chronic migraine. Cephalalgia 23: 820–824

    Article  PubMed  CAS  Google Scholar 

  69. Smith TR, Sunshine A, Stark SR et al. (2005) Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 45: 983–991

    Article  PubMed  Google Scholar 

  70. Tfelt-Hansen P, Iversen HK (1991) Subcutaneous sumatriptan in acute migraine. JAMA 266: 2703–2704

    Article  Google Scholar 

  71. Wilmshurst PT, Pearson MJ, Nightingale S et al. (2004) Inheritance of persistent foramen ovale and atrial septal defects and the relationship to familial migraine with aura. Heart 90: 1245–1247

    Article  Google Scholar 

  72. Zschiedrich M, Heidrich H, Dienes HP (1985) Ergotismus: Epidemiologie, Pathogenese, Histomorphologie, Diagnostik und Therapie. Med Klin 80: 721–727

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Prof. Dr. Hans-Christoph Diener hat Honorare für die Teilnahme an klinischen Tests, die Mitwirkung an Beratungsgremien und Vortragstätigkeiten erhalten von: Addex Pharma, Allergan, Almirali, Astra-Zeneca, Bayer Vital, Berlin Chemie, CoLucid, Böhringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Lilly, La Roche, 3M Media, MSD, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brümmer, Sanofi Aventis, Weber & Weber.

Finanzielle Untersützung für Forschungsprojekte wurde zur Verfügung gestellt von Allergan, Almirali, Astra-Zeneca, Bayer, GlaxoSmithKline, Janssen-Cilag, Pfizer.

Die Kopfschmerzforschung an der Abteilung für Neurologie in Essen erhält Förderungsmittel von der Deutschen Forschungsgemeinschaft (DFG), dem Bundesministerium für Bildung und Forschung (BMBF) und der Europäischen Union.

Prof. Dr. Hans-Christoph Diener hat keine Eigentümerinteressen und hält keine Anteile an einem Pharmaunternehmen.

Author information

Authors and Affiliations

  1. Universitätsklinik für Neurologie und Westdeutsches Kopfschmerzzentrum, Universitätsklinikum Essen, Hufelandstraße 55, 45147 , Essen, Deutschland

    H.-C. Diener & Z. Katsarava

  2. Neurologischen Klinik, Kliniken der Stadt Köln, Krankenhaus Merheim, Köln, Deutschland

    V. Limmroth

Authors
  1. H.-C. Diener
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Katsarava
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Limmroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H.-C. Diener.

Additional information

Aktualisierte Version des Beitrags von Diener HC, Slomke MA, Limmroth V (2007) Kopfschmerzen und Migräne. Nervenarzt [Suppl1] 78: 7–14

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diener, HC., Katsarava, Z. & Limmroth, V. Aktuelle Diagnostik und Therapie der Migräne. Schmerz 22 (Suppl 1), 51–60 (2008). https://doi.org/10.1007/s00482-007-0619-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00482-007-0619-3

Schlüsselwörter

Keywords

Search

Navigation